Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT
CM313 PHASE I CLINICAL STUDY DATA ACCEPTED FOR POSTER SESSION AT THE 28TH EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS 2023

This announcement is made by Keymed Biosciences Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Company is pleased to announce that the latest data from the Phase I clinical study of CM313 (a humanized monoclonal antibody targeting CD38), a Class I innovative drug developed by the Company, for the treatment of relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory lymphoma were presented as a poster presentation at the 28th European Hematology Association (EHA) Congress 2023.

This Phase I study (NCT04818372) aimed to evaluate the safety and preliminary efficacy of CM313 in patients with RRMM and relapsed/refractory lymphoma (currently limited to Waldenstrom's macroglobulinemia and marginal zone lymphoma (MZL)).

As of October 10, 2022, a total of 34 patients (31 RRMM and 3 MZL) were enrolled in the study. In safety assessments, CM313 was well-tolerated. The dose was successfully escalated up to 16.0 mg/kg, and maximum tolerated dose was not reached. No dose-limiting toxicity was observed. The most common treatment-related adverse events (occurring in ≥20% of patients) were infusion-related reactions and decreased cell counts in lymphocytes, white blood cells and neutrophils. All infusion-related reactions were grade 1 or 2 and occurred during the first and/or second infusions.

Among the 29 RRMM patients who had at least one post-baseline efficacy evaluation, the overall response rate (ORR) was 34.5%. The median progression-free survival (PFS) was 132 days, and the median overall survival (OS) was not reached.

CM313 exhibited a tolerable and manageable safety profile in general in this study. Moreover, CM313 at dose levels of ≥2.0 mg/kg yielded preliminary efficacy in patients with RRMM.

About CM313

CM313 is a humanized monoclonal antibody targeting CD38. CM313 is the first domestically developed anti-CD38 antibody with investigational new drug (IND) approval by the National Medical Products Administration (NMPA) in China. Given the encouraging efficacy in pre-clinical studies, the Company believes that CM313 has the potential to become an innovative treatment option for relapsed/refractory multiple myeloma, lymphoma and other hematological malignancies.

This announcement is made by the Company on a voluntary basis to provide information to shareholders and potential investors of the Company. There is no assurance that the Company will ultimately develop, market and/or commercialize CM313 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, June 12, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive Directors.